DISCOVER
Telemedicine technologies
Our story,
our strength
Telemedicine Technologies is the publisher of e-Health solutions, market leader in the field of Clinical Research with its CleanWeb™ solution, a secure Internet platform dedicated to the electronic management of clinical trials and registries.
For over 20 years, our company has been working to facilitate clinical research and empower all kind of clinical trials all around the world. Our solution CleanWeb™ for the electronic management of phase I-IV clinical trials, registries, observational studies and early access programmes is used in more than 64 different countries, more than 5,500 studies are ongoing or have been completed on our e-platform and more than 2 million patients have already been recruited via our solution.
From leading pharmaceutical companies to biotech start-ups and public hospitals, we are proud to support the activities of over 20,000 investigative centres and 50,000 users worldwide.
Our CleanWeb solution is ISO9001:2015 certified and compliant with the GAMP5 information system validation methodology. CDISC/ODM certified, we have been a global expert in data management for 20 years.
Our solution has an extremely high adoption rate, thanks to intuitive interfaces and our commitment to creating solutions tailored to our users’ needs. We have Qualiopi certification for training, a distinction that testifies to our constant concern for quality and customer satisfaction. In 2021 our training courses had an excellent customer satisfaction rate of 97%.
OUR TEAM
YOANNI TH. MATSAKIS
President
He is an aeronautical and space engineer (Sup’aéro), and worked for CNES (Centre National des Etudes Spatiales) and then for the MEDES (Institut de Médecine & Physiologie Spatiales), where he joined the project team of several manned space missions as Scientific and Responsible for the development of on board equipment for the astronauts physiological follow-up. Then he launched an important research and development program, which results in the creation of the company in 2000.
HUGUES GOURBAT
CEO
He is graduated from the Ecole Centrale Paris and the Business Administration Institute of the Paris University, and is a former Accenture partner. He joined the company in 2016 during the merger of TRIACYS. As General Director, he is an Executive Committee member and is responsible for the administrative, financial and human resources management.
DR. PHILIPPE HARAN
CEO and Business Development Director
Doctor, HEC graduate, Philippe brings the company his double skills. After a career in the pharmaceutical industry and as a CRO executive, he built strong experience in the field of clinical research and health innovations. He joined the company in 2016, and is an Exe
HOCINE MOKHTARI
Technical director
After graduating in computer engineering, he joined the company soon after its creation. He knows very well all the society’s applications. True expert on software development, he always has the right technical.
A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT
64 +
countries
involved
20 000 +
investigational
Centres
3 million +
patients
in database
50 000 +
users
worlwide
LATEST NEWSOUR NEWS >
June 27, 2024
25 September 2024 from 4:00PM to 5:30PM (CEST) Webinar Overview It has been demonstrated that using standards from the start of clinical research studies (i.e. protocol and CRF development) can save significant time and resources and results in higher quality research. Unfortunately, it is not always clear how to select the appropriate standards for the […]
June 27, 2024
Applied Clinical Trials Online ACT: How can data management challenges be addressed? Specifically, is there any opportunity to address them with artificial intelligence (AI)? Lacroix: There is a lot of opportunity across the life cycle to assist with this and it’s interesting because historically it was always: we want to throw people at some of […]
June 27, 2024
Fiercebiotech Experts recommend that CGT manufacturers proactively design a comprehensive market access strategy early in clinical development and commercial planning timelines, ideally more than three years prior to launch. This strategy should focus on addressing the nuanced market access challenges for such treatments, including but not limited to, distribution network design, tailored commercial site engagement, […]